摘要
目的以宫颈癌者为对象,探究行HE4(人附睾上皮分泌蛋白4)和CEA(癌胚抗原)、SCC-Ag(血清鳞状细胞癌抗原)和CYFRA21-1(细胞角蛋白19片段)联合检测的效果。方法把2018年1月至2020年12月时段我院接收的100例宫颈癌患者作为疾病组,同期另选取到医院行健康检查者100例作为对照组。实施酶联免疫吸附法与电化学发光法对对象的HE4和CEA、SCC-Ag和CYFRA21-1水平实施检测。结果在比较对象HE4、CEA、SCC-Ag、CYFRA21-1血清水平阳性率中,较疾病组,对照组结果所占比更低(P<0.05)。在比较对象HE4、CEA、SCC-Ag、CYFRA21-1血清水平中,较疾病组,对照组数据评分结果更低(P<0.05)。结论在宫颈癌诊断中,联合检测血清HE4、CEA、SCC-Ag、CYFRA21-1水平中,诊断准确率高,能为后期临床治疗宫颈癌提供依据支持。
Objective To study the clinical value of HE4(human epididymis protein 4),CEA(carcino-embryonic antigen),SCC-Ag(squamous cell carcinoma antigen)and CYFRA21-1(cytokeratin-19-fragment antigen 21-1)on diagnosis of cervical carcinoma.Methods 100 cervical carcinoma patients treated from January 2018 to December 2020 in our hospital were selected as disease group;over the same time period,100 healthy checkups were selected as control group.Enzyme-linked immunosorbent assay and electrochemiluminescence were used to measure the HE4,CEA,SCC-Ag and CYFRA21-1 contents.Results The positive rates of HE4,CEA,SCC-Ag and CYFRA21-1 in control group were lower than disease group(P<0.05);HE4,CEA,SCC-Ag and CYFRA21-1 contents in control group were lower than disease group(P<0.05).Conclusion HE4,CEA,SCC-Ag and CYFRA21-1 combined examination can increase the diagnosis accuracy of cervical carcinoma,providing basis on the subsequent treatment.
作者
刘亚红
邱育红
王欣
Liu Yahong;Qiu Yuhong;Wang Xin(Obstetrics And Gynecology Department,The Second Affiliated Hospital Of Shaanxi University Of Chinese Medicine,Xianyang 712000,Shanxi,China)
出处
《贵州医药》
CAS
2022年第6期843-844,847,共3页
Guizhou Medical Journal
关键词
宫颈癌
人附睾上皮分泌蛋白4
癌胚抗原
血清鳞状细胞癌抗原
细胞角蛋白19片段
cervical carcinoma
human epididymis protein 4
carcino-embryonic antigen
squamous cell carcinoma antigen
cytokeratin-19-fragment antigen 21-1